Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.

18 Feb 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

A new Cochrane review did not find clear evidence that taking zinc supplements reduces the occurrence of middle ear infections or otitis media in healthy children.

18 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

Scientists battling malaria have earned a major victory. According to a Nature Genetics study, an international group of researchers has used genomics to decode the blueprint of Plasmodium falciparum - a strain of malaria most resistant to drugs that causes the most deaths around the world.

17 Feb 2010

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that the US Patent and Trademark Office has issued two new patents covering methods of treatment and methods of preparation for the Company’s Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.

17 Feb 2010

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

16 Feb 2010

New pain management options for patients undergoing knee or hip replacements

Patients undergoing knee or hip replacements recover more quickly when treated with targeted pain-blocking medications that may eliminate the need for general anesthesia during surgery and intravenous narcotics drugs after surgery.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Obese adolescents who receive laparoscopic adjustable gastric banding lose excess weight

A higher percentage of severely obese adolescents who received laparoscopic adjustable gastric banding lost more than 50 percent of excess weight and experienced greater benefits to health and quality of life compared to those in an intensive lifestyle management program, according to a study in the February 10 issue of JAMA.

10 Feb 2010

Acupuncture: An effective pain management therapy for pediatric patients

Doctors at Rush University Medical Center are offering pediatric patients diagnosed with chronic illnesses acupuncture therapy to help ease the pain and negative side effects like nausea, fatigue, and vomiting caused by chronic health conditions and intensive treatments.

10 Feb 2010

New tool may help standardize use of CT scans in children with minor head injuries

A new tool may help standardize the use of computed tomography (CT scans) in children with minor head injury and help reduce the number of scans, according to a new study in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj091421.pdf.

9 Feb 2010

Three in ten overweight teenagers think they are underweight

Three in ten overweight teens believe they are actually underweight or "about right," according to a study of more than 65,000 high school students.

9 Feb 2010

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.

9 Feb 2010

Strativa Pharmaceuticals' Zuplenz NDA: FDA issues complete response letter

Strativa Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for Zuplenz® (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.

6 Feb 2010

FDA investigates Salmonella Montevideo outbreak in Italian sausage products

The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.

5 Feb 2010

Vomiting News and Research

Further Reading

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Study: Researchers use genomics to decode blueprint of Plasmodium falciparum

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

New pain management options for patients undergoing knee or hip replacements

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

FDA grants approval for Abbott's antiretroviral medication Norvir

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Study shows more women die of heart disease each year than men

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Obese adolescents who receive laparoscopic adjustable gastric banding lose excess weight

Acupuncture: An effective pain management therapy for pediatric patients

New tool may help standardize use of CT scans in children with minor head injuries

Three in ten overweight teenagers think they are underweight

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Strativa Pharmaceuticals' Zuplenz NDA: FDA issues complete response letter

FDA investigates Salmonella Montevideo outbreak in Italian sausage products

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News